All In Biotech

Drug Trial Radar · NCT06717074

A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease

A Randomized, Double-blind, Placebo-controlled Phase IIa Trial to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Repeated Subcutaneously Administered RBD4059 in Participants With Stable Coronary Artery Disease

Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Aug 28, 2024

Primary completion

Apr 29, 2026

Study completion Apr 29, 2026

Sponsor

Lead sponsor
Ribocure Pharmaceuticals ABIndustry
Sponsor type
Industry
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the safety of drug RBD4059, and also if drug RBD4059 works to treat stable coronary artery disease in adults. The main questions the trial aim to answer are: What medical problems may participants experience when taking drug RBD4059? Researchers will compare drug RBD4059 to a placebo to see if drug RBD4059 works to treat stable coronary artery disease. Participants will: Receive drug RBD4059 or a placebo. Visit the clinic 11 or 12 times during 11 or 14 months for checkups and tests, depending on which treatment group they belong to.

Conditions

  • Stable Coronary Artery Disease CAD

Interventions

  • RBD4059Drug

    RBD4059, active drug.

  • PlaceboDrug

    Placebo that is identical in appearance and volume to the doses of active IMP.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency, intensity and seriousness of reported AEs, SAEs and AEs of special interest (AESIs) during the trial.Time frame: From baseline until end of trial at week 48 or 60, depending on the dose group.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ribocure Clinic

    Mölndal, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.